Mortality was significantly decreased in patients who received plasma with an anti-RBD IgG titer of ≥1:1350 within 72 hours of admission  44 hours after hospitalization is optimal for transfusing COVID-19 patients with high-titer CP in order to prevent mortality  0,6% of patients developed significant adverse events related to plasma transfusion, including allergic reactions. This evidence concerns the gene CP and COVID-19.